Protagenic Therapeutics, Inc. (PTIX)

Protagenic Therapeutics, Inc. (PTIX) — VMCI valuation read

Across 120 indicators, Protagenic Therapeutics, Inc. (PTIX) lands at VMCI 38/100. The Healthcare sector median is 50, so the 12-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on PTIX in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, PTIX trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of -1.9x leaves covenant headroom for PTIX on the trailing balance sheet.

PTIX rose 0.6% over the trailing 7 days, with a -9.2% read on a 30-day basis.